Molecular Neurobiology

, Volume 44, Issue 2, pp 142–159 | Cite as

Neuroprotection by Spice-Derived Nutraceuticals: You Are What You Eat!

  • Ramaswamy Kannappan
  • Subash Chandra Gupta
  • Ji Hye Kim
  • Simone Reuter
  • Bharat Bhushan Aggarwal


Numerous lines of evidence indicate that chronic inflammation plays a major role in the development of various neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, brain tumor, and meningitis. Why these diseases are more common among people from some countries than others is not fully understood, but lifestyle factors have been linked to the development of neurodegenerative diseases. For example, the incidence of certain neurodegenerative diseases among people living in the Asian subcontinent, where people regularly consume spices, is much lower than in countries of the western world. Extensive research over the last 10 years has indicated that nutraceuticals derived from such spices as turmeric, red pepper, black pepper, licorice, clove, ginger, garlic, coriander, and cinnamon target inflammatory pathways, thereby may prevent neurodegenerative diseases. How these nutraceuticals modulate various pathways and how they exert neuroprotection are the focus of this review.


Neurodegenerative diseases Nutraceuticals Neuroprotection Spices Inflammation Alzheimer’s disease Parkinson’s disease 





Amyloid beta peptide


Alzheimer’s disease


Aged garlic extract


Brain-derived neurotrophic factor


Chemokine receptor type 5




Early growth response-1


Extracellular signal-regulated kinases


Beta-amyloid fibrils




Inducible nitric oxide synthase


c-Jun N-terminal kinase




Mitogen-activated protein kinase


Monocyte chemotactic protein 1


Macrophage inflammatory protein-1 β


1-Methyl-4-phenylpyridnium ion




Nuclear factor kappa-B


Neurotrophin receptor


Parkinson’s disease


Prion protein


Protease-resistant prion protein


Protein patched homolog 1


Reactive oxygen species




Sonic Hedgehog


Toll-like receptor


TNF-related apoptosis-inducing ligand


Transmissible spongiform encephalopathies


Vascular endothelial growth factor



Dr. Aggarwal is the Ransom Horne, Jr., Professor of Cancer Research. This work was partly supported by a grant from a core grant from the National Institutes of Health (CA-16672), a program project grant from National Institutes of Health (NIH CA-124787-01A2), and a grant from the Center for Targeted Therapy of MD Anderson Cancer Center. We thank Michael Worley, Department of Scientific Publications, for editorial assistance.


  1. 1.
    Anonymus (2010) The market outlook for neurodegenerative diseases: epidemiology, market size, current treatments and future innovation. [Report] Available from:
  2. 2.
    Mark C (2010) Neurodegenerative diseases: next-generation drugs for four major disorders. [Report] Available from:
  3. 3.
    Marchetti B, Abbracchio MP (2005) To be or not to be (inflamed)—is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 26:517–525PubMedGoogle Scholar
  4. 4.
    Amor S et al (2010) Inflammation in neurodegenerative diseases. Immunology 129:154–169PubMedGoogle Scholar
  5. 5.
    Galimberti D et al (2008) Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci 1:30–41PubMedGoogle Scholar
  6. 6.
    Kunnumakkara AB et al (2009) Traditional uses of spices: an overview. In: Aggarwal BB, Kunnumakkara AB (eds) Molecular targets and therapeutic uses of spices. World Scientific, New Jersey, pp 1–24Google Scholar
  7. 7.
    Aggarwal BB et al (2009) Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med Maywood 234:825–849PubMedGoogle Scholar
  8. 8.
    Aggarwal BB et al (2008) Potential of spice-derived phytochemicals for cancer prevention. Planta Med 74:1560–1569PubMedGoogle Scholar
  9. 9.
    Gupta SC et al. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29:405–434Google Scholar
  10. 10.
    Ono K et al (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res 75:742–750PubMedGoogle Scholar
  11. 11.
    Kuner P et al (1998) Beta-amyloid binds to p57NTR and activates NFkappaB in human neuroblastoma cells. J Neurosci Res 54:798–804PubMedGoogle Scholar
  12. 12.
    Giri RK et al (2003) Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol 170:5281–5294PubMedGoogle Scholar
  13. 13.
    Defossez A et al (1986) Immunohistochemical study of the basic lesions of Alzheimer’s disease. Encephale 12:161–168PubMedGoogle Scholar
  14. 14.
    Wilcock DM et al (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 1:1591–1595PubMedGoogle Scholar
  15. 15.
    Thakur MK (2000) Alzheimer’s disease—a challenge in the new millennium. Curr Sci 79:29–36Google Scholar
  16. 16.
    Berg L et al (1993) Neuropathological indexes of Alzheimer’s disease in demented and nondemented persons aged 80 years and older. Arch Neurol 50:349–358PubMedGoogle Scholar
  17. 17.
    Mattson MP, Rydel RE (1996) Alzheimer’s disease. Amyloid ox-tox transducers. Nature 382:674–675PubMedGoogle Scholar
  18. 18.
    Giri RK et al (2004) Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J Neurochem 91:1199–1210PubMedGoogle Scholar
  19. 19.
    Yang F et al (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892–5901PubMedGoogle Scholar
  20. 20.
    Ryu EK et al (2006) Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem 49:6111–6119PubMedGoogle Scholar
  21. 21.
    Park SY, Kim DS (2002) Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer’s disease. J Nat Prod 65:1227–1231PubMedGoogle Scholar
  22. 22.
    Frautschy SA et al (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 22:993–1005PubMedGoogle Scholar
  23. 23.
    Chonpathompikunlert P et al. Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer’s disease. Food Chem Toxicol 48:798–802Google Scholar
  24. 24.
    Chauhan NB (2006) Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer’s transgenic model Tg2576. J Ethnopharmacol 108:385–394PubMedGoogle Scholar
  25. 25.
    Gupta VB et al (2009) Garlic extract exhibits antiamyloidogenic activity on amyloid-beta fibrillogenesis: relevance to Alzheimer’s disease. Phytother Res 23:111–115PubMedGoogle Scholar
  26. 26.
    Gupta VB, Rao KS (2007) Anti-amyloidogenic activity of S-allyl-L-cysteine and its activity to destabilize Alzheimer’s beta-amyloid fibrils in vitro. Neurosci Lett 429:75–80PubMedGoogle Scholar
  27. 27.
    Peng Q et al (2002) Neuroprotective effect of garlic compounds in amyloid-beta peptide-induced apoptosis in vitro. Med Sci Monit 8:BR328–BR337PubMedGoogle Scholar
  28. 28.
    Iuvone T et al (2006) The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. J Pharmacol Exp Ther 317:1143–1149PubMedGoogle Scholar
  29. 29.
    Huang SH et al (2008) Protective effects of Angelica sinensis extract on amyloid beta-peptide-induced neurotoxicity. Phytomedicine 15:710–721PubMedGoogle Scholar
  30. 30.
    Yan JJ et al (2004) Protection against beta-amyloid peptide-induced memory impairment with long-term administration of extract of Angelica gigas or decursinol in mice. Prog Neuropsychopharmacol Biol Psychiatry 28:25–30PubMedGoogle Scholar
  31. 31.
    Lemkul JA, Bevan DR Destabilizing Alzheimer’s Abeta(42) protofibrils with morin: mechanistic insights from molecular dynamics simulations. Biochemistry 49:3935–3946Google Scholar
  32. 32.
    Guo JP et al Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer’s disease therapy. J Alzheimers Dis 19:1359–1370Google Scholar
  33. 33.
    Chung YK et al (2001) Inhibitory effect of ursolic acid purified from Origanum majorana L on the acetylcholinesterase. Mol Cells 11:137–143PubMedGoogle Scholar
  34. 34.
    Jukic M et al (2007) In vitro acetylcholinesterase inhibitory properties of thymol, carvacrol and their derivatives thymoquinone and thymohydroquinone. Phytother Res 21:259–261PubMedGoogle Scholar
  35. 35.
    Lang AE, Lozano AM (1998) Parkinson’s disease. Second of two parts. N Engl J Med 339:1130–1143PubMedGoogle Scholar
  36. 36.
    Jomova K et al. Metals, oxidative stress and neurodegenerative disorders. Mol Cell BiochemGoogle Scholar
  37. 37.
    Olanow CW et al (2003) Neuroprotection for Parkinson’s disease: prospects and promises. Ann Neurol 53(Suppl 3):S1–S2PubMedGoogle Scholar
  38. 38.
    Drukarch B et al (2006) The antioxidant anethole dithiolethione inhibits monoamine oxidase-B but not monoamine oxidase A activity in extracts of cultured astrocytes. J Neural Transm 113:593–598PubMedGoogle Scholar
  39. 39.
    Martin TM et al (2006) The effect of conventional and sustained delivery of thymoquinone and levodopa on SH-SY5Y human neuroblastoma cells. Biomed Sci Instrum 42:332–337PubMedGoogle Scholar
  40. 40.
    Radad K et al (2009) Thymoquinone protects dopaminergic neurons against MPP+ and rotenone. Phytother Res 23:696–700PubMedGoogle Scholar
  41. 41.
    Kim SJ et al (2006) Carnosol, a component of rosemary (Rosmarinus officinalis L.) protects nigral dopaminergic neuronal cells. NeuroReport 17:1729–1733PubMedGoogle Scholar
  42. 42.
    Filomeni G et al Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson’s disease. Neurobiol AgingGoogle Scholar
  43. 43.
    Qu W et al (2009) Kaempferol derivatives prevent oxidative stress-induced cell death in a DJ-1-dependent manner. J Pharmacol Sci 110:191–200PubMedGoogle Scholar
  44. 44.
    Xu Q et al (2008) Neuroprotective effect of the natural iron chelator, phytic acid in a cell culture model of Parkinson’s disease. Toxicology 245:101–108PubMedGoogle Scholar
  45. 45.
    Bournival J et al (2009) Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol 29:1169–1180PubMedGoogle Scholar
  46. 46.
    Vauzour D et al Sulforaphane protects cortical neurons against 5-S-cysteinyl-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes. Mol Nutr Food Res 54:532–542Google Scholar
  47. 47.
    Tarozzi A et al (2009) Sulforaphane as an inducer of glutathione prevents oxidative stress-induced cell death in a dopaminergic-like neuroblastoma cell line. J Neurochem 111:1161–1171PubMedGoogle Scholar
  48. 48.
    Han JM et al (2007) Protective effect of sulforaphane against dopaminergic cell death. J Pharmacol Exp Ther 321:249–256PubMedGoogle Scholar
  49. 49.
    Wang MS et al. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson’s disease cell model. BMC Neurosci 11:57Google Scholar
  50. 50.
    Pandey N et al (2008) Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol 115:479–489PubMedGoogle Scholar
  51. 51.
    Li X et al (2008) c-Jun N-terminal kinase mediates lactacystin-induced dopamine neuron degeneration. J Neuropathol Exp Neurol 67:933–944PubMedGoogle Scholar
  52. 52.
    Wang W et al (2004) SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease. Neurosci Res 48:195–202PubMedGoogle Scholar
  53. 53.
    Pan J et al (2007) Expression of FasL and its interaction with Fas are mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced rat model of Parkinson disease. Neurosci Lett 428:82–87PubMedGoogle Scholar
  54. 54.
    Yu S et al Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res 13:55–64Google Scholar
  55. 55.
    Wang J et al (2009) Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem Pharmacol 78:178–183PubMedGoogle Scholar
  56. 56.
    Harish G et al Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: implications for Parkinson’s disease. Bioorg Med Chem 18:2631–2638Google Scholar
  57. 57.
    Beal MF (2009) Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3):S189–S194PubMedGoogle Scholar
  58. 58.
    Ono K et al (2008) Alpha-synuclein assembly as a therapeutic target of Parkinson’s disease and related disorders. Curr Pharm Des 14:3247–3266PubMedGoogle Scholar
  59. 59.
    Jagatha B et al (2008) Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson’s disease explained via in silico studies. Free Radic Biol Med 44:907–917PubMedGoogle Scholar
  60. 60.
    Mythri RB et al (2007) Mitochondrial complex I inhibition in Parkinson’s disease: how can curcumin protect mitochondria? Antioxid Redox Signal 9:399–408PubMedGoogle Scholar
  61. 61.
    Chen J et al (2006) Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis 11:943–953PubMedGoogle Scholar
  62. 62.
    Zbarsky V et al (2005) Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson’s disease. Free Radic Res 39:1119–1125PubMedGoogle Scholar
  63. 63.
    Rajeswari A, Sabesan M (2008) Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson’s disease induced by MPTP neurodegeneration in mice. Inflammopharmacol 16:96–99Google Scholar
  64. 64.
    Yang S et al (2008) Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochem Res 33:2044–2053PubMedGoogle Scholar
  65. 65.
    Goel A et al (2008) Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75:787–809PubMedGoogle Scholar
  66. 66.
    Ramassamy C (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545:51–64PubMedGoogle Scholar
  67. 67.
    Ortiz-Ortiz MA et al Curcumin exposure induces expression of the Parkinson’s disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells. Neurosci Lett 468:120–124Google Scholar
  68. 68.
    Kabuto H et al (2005) Zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] prevents 6-hydroxydopamine-induced dopamine depression in mouse striatum and increases superoxide scavenging activity in serum. Neurochem Res 30:325–332PubMedGoogle Scholar
  69. 69.
    Kabuto H et al (2007) Eugenol [2-methoxy-4-(2-propenyl)phenol] prevents 6-hydroxydopamine-induced dopamine depression and lipid peroxidation inductivity in mouse striatum. Biol Pharm Bull 30:423–427PubMedGoogle Scholar
  70. 70.
    Zhang ZT et al Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo. Acta Pharmacol Sin 31:900–906Google Scholar
  71. 71.
    Bangaru ML et al Curcumin (diferuloylmethane) induces apoptosis and blocks migration of human medulloblastoma cells. Anticancer Res 30:499–504Google Scholar
  72. 72.
    Elamin MH et al Curcumin inhibits the Sonic Hedgehog signaling pathway and triggers apoptosis in medulloblastoma cells. Mol Carcinog 49:302–314Google Scholar
  73. 73.
    Schaaf C et al (2010) Curcumin inhibits the growth, induces apoptosis and modulates the function of pituitary folliculostellate cells. Neuroendocrinology 91:200–210PubMedGoogle Scholar
  74. 74.
    Aoki H et al (2007) Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72:29–39PubMedGoogle Scholar
  75. 75.
    Dhandapani KM et al (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem 102:522–538PubMedGoogle Scholar
  76. 76.
    Liu E et al (2007) Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol 85:263–270PubMedGoogle Scholar
  77. 77.
    Gao X et al (2005) Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria. J Exp Ther Oncol 5:39–48PubMedGoogle Scholar
  78. 78.
    Kim SY et al (2005) Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem Biophys Res Commun 337:510–516PubMedGoogle Scholar
  79. 79.
    Karmakar S et al (2007) Curcumin suppressed anti-apoptotic signals and activated cysteine proteases for apoptosis in human malignant glioblastoma U87MG cells. Neurochem Res 32:2103–2113PubMedGoogle Scholar
  80. 80.
    Vanisree AJ, Ramanan R (2007) In vitro assessment of curcumin against murine neuroblastoma cells. Neuro Endocrinol Lett 28:204–212PubMedGoogle Scholar
  81. 81.
    Luthra PM et al (2009) Demethoxycurcumin induces Bcl-2 mediated G2/M arrest and apoptosis in human glioma U87 cells. Biochem Biophys Res Commun 384:420–425PubMedGoogle Scholar
  82. 82.
    Schaaf C et al (2009) Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo. Endocr Relat Cancer 16:1339–1350PubMedGoogle Scholar
  83. 83.
    Aravindan N et al (2008) Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther 7:569–576PubMedGoogle Scholar
  84. 84.
    Freudlsperger C et al (2008) Curcumin induces apoptosis in human neuroblastoma cells via inhibition of NFkappaB. Anticancer Res 28:209–214PubMedGoogle Scholar
  85. 85.
    Richeux F et al (1999) Cytotoxicity and genotoxicity of capsaicin in human neuroblastoma cells SHSY-5Y. Arch Toxicol 73:403–409PubMedGoogle Scholar
  86. 86.
    Kim DS, Oppel MN (2002) Shogaols from Zingiber officinale protect IMR32 human neuroblastoma and normal human umbilical vein endothelial cells from beta-amyloid(25–35) insult. Planta Med 68:375–376PubMedGoogle Scholar
  87. 87.
    Huang HC et al (2009) Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog 48:517–531PubMedGoogle Scholar
  88. 88.
    Tsai NM et al (2005) The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 11:3475–3484PubMedGoogle Scholar
  89. 89.
    Lee WH et al (2006) Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma. Pathobiology 73:141–148PubMedGoogle Scholar
  90. 90.
    Tsai NM et al (2006) The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem 99:1251–1262PubMedGoogle Scholar
  91. 91.
    Lin PC et al (2008) Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. J Neurochem 106:1017–1026PubMedGoogle Scholar
  92. 92.
    Jang SW et al (2007) Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci USA 104:16329–16334PubMedGoogle Scholar
  93. 93.
    Qiang L et al (2008) Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol 75:1083–1092PubMedGoogle Scholar
  94. 94.
    Aktas O et al (2007) Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. J Neuroimmunol 184:17–26PubMedGoogle Scholar
  95. 95.
    Xie L et al (2009) Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 9:575–581PubMedGoogle Scholar
  96. 96.
    Chearwae W, Bright JJ (2008) 15-deoxy-Delta(12, 14)-prostaglandin J(2) and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte. J Clin Immunol 28:558–570PubMedGoogle Scholar
  97. 97.
    Fahey AJ et al (2007) Curcumin modulation of IFN-beta and IL-12 signalling and cytokine induction in human T cells. J Cell Mol Med 11:1129–1137PubMedGoogle Scholar
  98. 98.
    Theoharides TC (2009) Luteolin as a therapeutic option for multiple sclerosis. J Neuroinflammation 6:29PubMedGoogle Scholar
  99. 99.
    Sternberg Z et al (2009) Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-beta. J Neuroinflammation 6:28PubMedGoogle Scholar
  100. 100.
    Sternberg Z et al (2008) Quercetin and interferon-beta modulate immune response(s) in peripheral blood mononuclear cells isolated from multiple sclerosis patients. J Neuroimmunol 205:142–147PubMedGoogle Scholar
  101. 101.
    Sayyah M et al (2004) Anticonvulsant activity and chemical composition of Artemisia dracunculus L. essential oil. J Ethnopharmacol 94:283–287PubMedGoogle Scholar
  102. 102.
    Song J et al (2008) DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy. Neuroscience 156:722–728PubMedGoogle Scholar
  103. 103.
    Jager AK et al (2009) Bioassay-guided isolation of apigenin with GABA-benzodiazepine activity from Tanacetum parthenium. Phytother Res 23:1642–1644PubMedGoogle Scholar
  104. 104.
    Dib B, Falchi M (1996) Convulsions and death induced in rats by Tween 80 are prevented by capsaicin. Int J Tissue React 18:27–31PubMedGoogle Scholar
  105. 105.
    Mehla J et al Protective effect of curcumin against seizures and cognitive impairment in a pentylenetetrazole-kindled epileptic rat model. Life SciGoogle Scholar
  106. 106.
    Kulkarni SK, Dhir A An overview of curcumin in neurological disorders. Indian J Pharm Sci 72:149–154Google Scholar
  107. 107.
    Gupta YK et al (2009) Protective effect of curcumin against kainic acid induced seizures and oxidative stress in rats. Indian J Physiol Pharmacol 53:39–46PubMedGoogle Scholar
  108. 108.
    Muller M et al (2006) Effect of eugenol on spreading depression and epileptiform discharges in rat neocortical and hippocampal tissues. Neuroscience 140:743–751PubMedGoogle Scholar
  109. 109.
    Neto AC et al (2009) The role of polar phytocomplexes on anticonvulsant effects of leaf extracts of Lippia alba (Mill.) N.E. Brown chemotypes. J Pharm Pharmacol 61:933–939PubMedGoogle Scholar
  110. 110.
    D’Hooge R et al (1996) Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists. Arzneimittelforschung 46:557–560PubMedGoogle Scholar
  111. 111.
    Joshi D et al (2005) Protective effect of quercetin on alcohol abstinence-induced anxiety and convulsions. J Med Food 8:392–396PubMedGoogle Scholar
  112. 112.
    Song J et al (2007) Seizure suppression by top1 mutations in Drosophila. J Neurosci 27:2927–2937PubMedGoogle Scholar
  113. 113.
    Ellens DJ et al (2009) Development of spike-wave seizures in C3H/HeJ mice. Epilepsy Res 85:53–59PubMedGoogle Scholar
  114. 114.
  115. 115.
    Coppen A, Bailey J (2000) Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 60:121–130PubMedGoogle Scholar
  116. 116.
    Goldman LS et al (1999) Awareness, diagnosis, and treatment of depression. J Gen Intern Med 14:569–580PubMedGoogle Scholar
  117. 117.
    NCCAM (2004) What is complementary and alternative medicine? Available from:
  118. 118.
    Kulkarni SK et al (2008) Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacol Berl 201:435–442Google Scholar
  119. 119.
    Kulkarni S et al (2009) Potentials of curcumin as an antidepressant. ScientificWorldJournal 9:1233–1241PubMedGoogle Scholar
  120. 120.
    Xu Y et al (2005) Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 82:200–206PubMedGoogle Scholar
  121. 121.
    Nakazawa T et al (2003) Antidepressant-like effects of apigenin and 2, 4, 5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. Biol Pharm Bull 26:474–480PubMedGoogle Scholar
  122. 122.
    Irie Y et al (2004) Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein-III in the hippocampus. Brain Res 1011:243–246PubMedGoogle Scholar
  123. 123.
    Li S et al (2007) Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. Life Sci 80:1373–1381PubMedGoogle Scholar
  124. 124.
    Lipton P (1999) Ischemic cell death in brain neurons. Physiol Rev 79:1431–1568PubMedGoogle Scholar
  125. 125.
    Jiang J et al (2007) Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol 561:54–62PubMedGoogle Scholar
  126. 126.
    Zhao J et al Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Neurochem Res 35:374–379Google Scholar
  127. 127.
    Rathore P et al (2008) Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. Neurochem Res 33:1672–1682PubMedGoogle Scholar
  128. 128.
    Shukla PK et al (2008) Anti-ischemic effect of curcumin in rat brain. Neurochem Res 33:1036–1043PubMedGoogle Scholar
  129. 129.
    Thiyagarajan M, Sharma SS (2004) Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci 74:969–985PubMedGoogle Scholar
  130. 130.
    Li CY, Cheng XS (2007) Effects of allicin on changes of hemorheology in focal cerebral ischemia-reperfusion injury. Zhongguo Zhong Yao Za Zhi 32:1314–1317PubMedGoogle Scholar
  131. 131.
    Ha SK et al (2008) Apigenin inhibits the production of NO and PGE2 in microglia and inhibits neuronal cell death in a middle cerebral artery occlusion-induced focal ischemia mice model. Neurochem Int 52:878–886PubMedGoogle Scholar
  132. 132.
    Lopez-Sanchez C et al (2007) Blood micromolar concentrations of kaempferol afford protection against ischemia/reperfusion-induced damage in rat brain. Brain Res 1182:123–137PubMedGoogle Scholar
  133. 133.
    Rivera F et al (2008) Reduction of ischemic brain damage and increase of glutathione by a liposomal preparation of quercetin in permanent focal ischemia in rats. Neurotox Res 13:105–114PubMedGoogle Scholar
  134. 134.
    Zhao J et al (2006) Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci Lett 393:108–112PubMedGoogle Scholar
  135. 135.
    Marchbanks RM et al (2003) A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr Res 65:33–38PubMedGoogle Scholar
  136. 136.
    Mizuno M et al (2008) The anthraquinone derivative Emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia. J Neural Transm 115:521–530PubMedGoogle Scholar
  137. 137.
    Caughey B et al (2003) Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol 77:5499–5502PubMedGoogle Scholar
  138. 138.
    Hafner-Bratkovic I et al (2008) Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein—a new mechanism for the inhibition of PrP(Sc) accumulation. J Neurochem 104:1553–1564PubMedGoogle Scholar
  139. 139.
    Weisfelt M et al (2007) Bacterial meningitis: a review of effective pharmacotherapy. Expert Opin Pharmacother 8:1493–1504PubMedGoogle Scholar
  140. 140.
    Davis LE et al (1994) In vitro synergism of concentrated Allium sativum extract and amphotericin B against Cryptococcus neoformans. Planta Med 60:546–549PubMedGoogle Scholar
  141. 141.
    Shen J et al (1996) Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Planta Med 62:415–418PubMedGoogle Scholar
  142. 142.
    Tajik H et al (2007) Interaction between curcumin and opioid system in the formalin test of rats. Pak J Biol Sci 10:2583–2586PubMedGoogle Scholar
  143. 143.
    Tajik H et al (2008) The effect of curcumin (active substance of turmeric) on the acetic acid-induced visceral nociception in rats. Pak J Biol Sci 11:312–314PubMedGoogle Scholar
  144. 144.
    Matsushita Y, Ueda H (2009) Curcumin blocks chronic morphine analgesic tolerance and brain-derived neurotrophic factor upregulation. NeuroReport 20:63–68PubMedGoogle Scholar
  145. 145.
    Baum L et al (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28:110–113PubMedGoogle Scholar
  146. 146.
    Masoumi A et al (2009) 1alpha, 25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 17:703–717PubMedGoogle Scholar
  147. 147.
    Ambegaokar SS et al (2003) Curcumin inhibits dose-dependently and time-dependently neuroglial cell proliferation and growth. Neuro Endocrinol Lett 24:469–473PubMedGoogle Scholar
  148. 148.
    Ghayur MN et al (2008) Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia. J Pharm Pharmacol 60:1375–1383PubMedGoogle Scholar
  149. 149.
    Theoharides TC et al (2007) Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol 601:423–430PubMedGoogle Scholar
  150. 150.
    Abila B et al (1993) Anticonvulsant effects of extracts of the West African black pepper, Piper guineense. J Ethnopharmacol 39:113–117PubMedGoogle Scholar
  151. 151.
    Guenette SA et al (2007) Pharmacokinetics of eugenol and its effects on thermal hypersensitivity in rats. Eur J Pharmacol 562:60–67PubMedGoogle Scholar
  152. 152.
    Zhan C, Yang J (2006) Protective effects of isoliquiritigenin in transient middle cerebral artery occlusion-induced focal cerebral ischemia in rats. Pharmacol Res 53:303–309PubMedGoogle Scholar
  153. 153.
    Yang JW et al (2005) The effects of Chinese herb Angelica in focal cerebral ischemia injury in the rat. Clin Hemorheol Microcirc 32:209–215PubMedGoogle Scholar
  154. 154.
    Cheng CY et al (2008) Ferulic acid reduces cerebral infarct through its antioxidative and anti-inflammatory effects following transient focal cerebral ischemia in rats. Am J Chin Med 36:1105–1119PubMedGoogle Scholar
  155. 155.
    Lin Z et al (2008) Herbal formula FBD extracts prevented brain injury and inflammation induced by cerebral ischemia-reperfusion. J Ethnopharmacol 118:140–147PubMedGoogle Scholar
  156. 156.
    Zhang L et al (2009) Z-ligustilide extracted from Radix Angelica Sinensis decreased platelet aggregation induced by ADP ex vivo and arterio-venous shunt thrombosis in vivo in rats. Yakugaku Zasshi 129:855–859PubMedGoogle Scholar
  157. 157.
    Unchern S et al (1994) Piperine, a pungent alkaloid, is cytotoxic to cultured neurons from the embryonic rat brain. Biol Pharm Bull 17:403–406PubMedGoogle Scholar
  158. 158.
    Qiang LQ et al (2009) Combined administration of the mixture of honokiol and magnolol and ginger oil evokes antidepressant-like synergism in rats. Arch Pharm Res 32:1281–1292PubMedGoogle Scholar
  159. 159.
    Yi LT et al (2009) Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice. Prog Neuropsychopharmacol Biol Psychiatry 33:616–624PubMedGoogle Scholar
  160. 160.
    Liontas A, Yeger H (2004) Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res 24:987–998PubMedGoogle Scholar
  161. 161.
    Lee YS et al (2002) Redox status-dependent regulation of cyclooxygenases mediates the capsaicin-induced apoptosis in human neuroblastoma cells. J Environ Pathol Toxicol Oncol 21:113–120PubMedGoogle Scholar
  162. 162.
    Amantini C et al (2007) Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem 102:977–990PubMedGoogle Scholar
  163. 163.
    Baek YM et al (2008) A comparative proteomic analysis for capsaicin-induced apoptosis between human hepatocarcinoma (HepG2) and human neuroblastoma (SK-N-SH) cells. Proteomics 8:4748–4767PubMedGoogle Scholar
  164. 164.
    DeKosky ST et al (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300:2253–2262PubMedGoogle Scholar
  165. 165.
    Ng TP et al (2006) Curry consumption and cognitive function in the elderly. Am J Epidemiol 164:898–906PubMedGoogle Scholar
  166. 166.
    Kennedy DO et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 91:1590–1597Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ramaswamy Kannappan
    • 1
  • Subash Chandra Gupta
    • 1
  • Ji Hye Kim
    • 1
  • Simone Reuter
    • 1
  • Bharat Bhushan Aggarwal
    • 1
  1. 1.Cytokine Research Laboratory, Department of Experimental TherapeuticsThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations